Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
Novartis acquires Regulus Therapeutics and potential first-in-class therapeutic
Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor for ADPKD to its renal pipeline.
Read more
European Commission gives green light to Roche’s PNH treatment
Roche has secured European Commission approval for its drug crovalimab, marking a significant advancement in the treatment of PNH.
Bavarian Nordic to manufacture 440,000 doses of mpox vaccine
Bavarian Nordic has entered into a significant agreement to manufacture 440,000 additional doses of its vaccine in response to the escalating mpox outbreak.
NHS must adapt for next wave of advanced therapies, warns ABPI
The NHS has made commendable progress in introducing advanced therapies, but it must accelerate preparations for the next wave.
J&J wins FDA approval for chemo-free treatment for lung cancer
The FDA has approved Johnson & Johnson’s new chemotherapy-free combination treatment for patients with non-small cell lung cancer.
WHO makes urgent call to companies developing mpox vaccines
The World Health Organization has made an urgent call to pharmaceutical companies producing mpox vaccines to submit a Expressions of Interest for Emergency Use Listing (EUL).
MHRA signs off on Astellas' gastric cancer treatment
Astellas Pharma has received approval from the UK’s MHRA for its innovative therapy designed to treat gastric cancer.
FDA nod for world's first needle-free allergic reaction treatment
The FDA has granted approval for an innovative epinephrine nasal spray, making it the first needle-free emergency treatment for potentially fatal allergic reactions.
AZ, GSK, Novartis, BMS and Sanofi lead Q2 2024 sales growth
The pharma industry shows strong growth into the second quarter of 2024, with companies reporting substantial YoY profit increases in Q2.
Loading posts...
« Previous
1
…
14
15
16
17
18
…
27
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View